Eve Health Group Limited.
EVE.ASXConsumer Staples
EVE Health Group (ASX: EVE) is an Australian life sciences company developing and commercialising innovative pharmaceutical products in high-growth therapeutic areas. Its lead assets, Dyspro and Libbo, utilise proprietary delivery technologies to improve
Market Data
$0.023
-0.0%$8.5M
-100000.0x
$-0.009
0.00%
-0.2%
Latest Earnings
Appendix 4D and Half Year Report
27 February 2026
EVE Health Group reported a widening H1 2026 loss of $848.5K (vs $806.9K loss in H1 2025) on sharply lower revenue of $632.9K, down 37% year-on-year, as the company transitioned from late-stage development into early commercial execution of its Dyspro™ and Libbo™ pharmaceutical products. Despite operational challenges, the company achieved key regulatory milestones, completed GMP manufacturing, commenced patient prescriptions, and secured $1.1M in capital raising to support commercialisation. Key points: Achieved key regulatory milestones: Dyspro™ achieved regulatory prerequisites (TGA Special Access Scheme and Authorised Prescriber pathways) in July 2025, enabling first patient prescriptions in September 2025; Successful capital raise of $1.1M to support commercial rollout, demonstrating investor confidence and providing funding runway for pharmaceutical product launches; Advanced manufacturing and distribution readiness: Dyspro™ completed GMP manufacture and commenced distribution; Libbo™ completed initial commercial manufacturing with finished inventory delivered to national distribution post-period
Recent Announcements
Becoming a substantial holder
A-WON PHARMA PTY LTD became a substantial holder in EVE Health Group Pty Ltd on 20 March 2026 by acquiring 20,000,000 fully paid ordinary shares (5.7% voting power) for $400,000 in cash, with Aman Madan listed as a director and associate.
Appendix 4D and Half Year Report
EVE Health Group reported a widening H1 2026 loss of $848.5K (vs $806.9K loss in H1 2025) on sharply lower revenue of $632.9K, down 37% year-on-year, as the company transitioned from late-stage development into early commercial execution of its Dyspro™ and Libbo™ pharmaceutical products. Despite operational challenges, the company achieved key regulatory milestones, completed GMP manufacturing, commenced patient prescriptions, and secured $1.1M in capital raising to support commercialisation. Key points: Achieved key regulatory milestones: Dyspro™ achieved regulatory prerequisites (TGA Special Access Scheme and Authorised Prescriber pathways) in July 2025, enabling first patient prescriptions in September 2025; Successful capital raise of $1.1M to support commercial rollout, demonstrating investor confidence and providing funding runway for pharmaceutical product launches; Advanced manufacturing and distribution readiness: Dyspro™ completed GMP manufacture and commenced distribution; Libbo™ completed initial commercial manufacturing with finished inventory delivered to national distribution post-period
Get real-time alerts for EVE
Receive AI-powered earnings summaries and instant notifications when Eve Health Group Limited. releases results.
Register Free